Find Your Next 10X Winner in the Burgeoning Shroom Boom

Remember when marijuana used to be taboo?

Back in 1970, when Richard Nixon passed the Controlled Substances Act as part of his “War on Drugs,” marijuana was considered a Schedule 1 drug – meaning it was listed next to cocaine and heroin as an extremely dangerous, extremely illegal substance with no “accepted medical use.”

Today, the global legal marijuana market measures $17 BILLION, and is growing at a 40% per year pace.

What happened?

Emerging science changed public perception, which paved the path for legalization and a marijuana “boom.”

Specifically, an abundance of academic research came out in the 2000s, which illustrated the medical benefits of marijuana. At the same time, Hollywood began to portray weed as being a friendly, fun drug in movies like Harold & Kumar and Step Brothers.

Marijuana became destigmatized…

Consumer attitudes shifted…

Changing public perception turned into growing public demand for legalization…

A few protests and bills later, marijuana wasn’t just legalized – it turned into one of the hottest consumer markets in the world.

If you missed out on investing early in the marijuana boom, don’t worry.

Right now, another Schedule 1 drug is in the first inning of following in marijuana’s explosive footsteps: psychedelics.

Yes. Those psychedelics. Magic mushrooms. LSD. MDMA. DMT.

For years and years, society has frowned up psychedelics as hard drugs to be avoided – but things weren’t always like that.

Rewind 70 years. Back in the 1950s, a group of pioneering psychiatrists in California led by Humphry Osmond actively experimented with psychedelics and finding that hallucinogenic drugs had immense therapeutic potential.

But sociopolitical backlash against “hippie culture” in the 1960s halted their research, and in 1970, psychedelics landed on Nixon’s Schedule 1 drug list.

The book was closed on psychedelic research.

Until the 2010s.

When the academic world reopened that book, and discovered a world of opportunity and untapped potential…

A pair of recent Johns Hopkins studies have found that the active ingredient in “magic mushrooms” (something called psilocybin) can significantly help with smoking cessation and reducing alcohol dependence.

An even more recent Johns Hopkins study published in 2020 found that psilocybin can relieve anxiety and depression levels in people with life-threatening cancer diagnoses four-times better than traditional antidepressants on the market.

That finding corroborates a previous NYU study, which found that psilocybin causes a “rapid and sustained” reduction in anxiety and depression levels in cancer patients.

Meanwhile, a recent UC Davis study found that psychedelic micro-dosing can produce beneficial behavioral effects in patients with mental health disorders.

The list of academic studies goes on and on.

And they are all coming to the same conclusion: psychedelic-inspired medicines have robust therapeutic potential.

The science is…